Business Context and Reporting Period
Nexentis Technologies Inc. (formerly N2OFF, Inc.) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The Company, incorporated in Nevada, operates primarily through two segments: Biotechnology (via its wholly-owned subsidiary MitoCareX Bio Ltd., acquired in October 2025) and Renewable Energy Projects (via NITO Renewable Energy, Inc. and joint ventures). The Company completed a 1-for-35 reverse stock split in September 2025. During the period, the Company classified its former Save Foods Ltd. operations and NTWO OFF Ltd. as discontinued operations, with the Save Foods business subsequently sold to Voice Assist, Inc. in March 2026.
Key Financial Metrics
| Metric | 2025 (USD) | 2024 (USD) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss (Continuing Ops) | $(3,595,000) | $(4,319,000) |
| Net Loss (Total) | $(4,156,000) | $(5,347,000) |
| Operating Loss | $(4,230,000) | $(3,283,000) |
| Cash and Cash Equivalents | $3,832,000 | $1,923,000 |
| Working Capital | $4,580,000 | $2,560,000 |
| Accumulated Deficit | $(38,557,000) | $(34,553,000) |
| Loss Per Share (Basic) | $(3.54) | $(27.74) |
Note: Financial figures are presented in thousands in the source text but converted to full dollars for clarity above. The Company reported no revenue from continuing operations.
Material Changes vs. Prior Period
- Acquisition of MitoCareX: In October 2025, the Company acquired 100% of MitoCareX Bio Ltd. for a total consideration of approximately $8.86 million (cash, stock, and contingent consideration). This introduced new Research and Development expenses of $179,000 and significant intangible assets ($4.43 million) and goodwill ($6.29 million).
- Discontinued Operations: The Company sold NTWO OFF Ltd. in April 2025 and classified Save Foods Ltd. as held for sale. Net loss from discontinued operations decreased to $(561,000) in 2025 from $(1,028,000) in 2024.
- Expense Increases: General and Administrative (G&A) expenses increased by 56% to $5.11 million, driven primarily by a rise in share-based compensation ($2.39 million vs. $1.06 million) and professional services.
- Financing Activity: Net cash provided by financing activities surged to $8.86 million (from $3.05 million), fueled by proceeds from Standby Equity Purchase Agreements (SEPA), a PIPE transaction, and promissory notes.
- Investing Activity: Net cash used in investing activities increased to $(3.23 million), primarily due to investments in solar projects and the cash portion of the MitoCareX acquisition.
Guidance, Outlook, and Risks
- Going Concern: The Company has incurred recurring losses and has an accumulated deficit of approximately $38.6 million. Management believes existing capital resources will support operations through the first quarter of 2027, but there is substantial doubt about the Company's ability to continue as a going concern without additional financing.
- Strategic Focus: The Company is pivoting to oncology biotechnology (MitoCareX) and renewable energy. MitoCareX is in the preclinical stage, focusing on Non-Small Cell Lung Cancer (NSCLC) and pancreatic cancer. No products are approved for commercial sale.
- Capital Requirements: The Company expects to incur significant losses for the foreseeable future and will require substantial additional capital to fund R&D, clinical trials, and renewable energy projects. Failure to secure financing could force a reduction in operations.
- Geopolitical Risks: Operations are heavily concentrated in Israel. The ongoing conflict and regional instability pose risks to workforce availability, supply chains, and asset safety. The Company notes that while a ceasefire was reached in September 2025, tensions escalated again in early 2026.
- Regulatory and Market Risks: As a smaller reporting company, the Company faces risks related to Nasdaq listing compliance (minimum bid price), volatility in stock price, and the high failure rate of early-stage biopharmaceutical development.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $3.83 million cash balance to fund operations through Q1 2027 given the high burn rate and lack of revenue.
- Contingent Consideration: Review the valuation and terms of the $2.14 million contingent consideration liability related to the MitoCareX acquisition, which includes potential future share issuances and cash payments tied to financing milestones.
- Save Foods Disposal: Confirm the closing details and consideration received for the sale of Save Foods Ltd. to Voice Assist, Inc., which closed in March 2026 (subsequent to the reporting period).
- Related Party Transactions: Scrutinize the extensive related party transactions, including loans and investments involving Pure Capital Ltd., Solterra, and directors who also serve on the boards of these entities.
- Stock Dilution: Monitor the impact of the SEPA II, PIPE warrants, and equity grants on shareholder dilution, particularly given the low share price ($0.625 as of March 30, 2026) and the 1-for-35 reverse split.